First FDA approved cannabis-based drug now available by prescription

The first cannabis-derived medication approved by the Food and Drug Administration is now available by prescription in every state, according to its manufacturer.

Epidiolex, manufactured by GW Pharmaceuticals, is intended to treat seizures associated with two rare and severe forms of epilepsy that begin in childhood. The drug is made of cannabidiol (CBD), a component of marijuana that doesn’t give users a high.

Continue reading “First FDA approved cannabis-based drug now available by prescription”

GW Pharmaceuticals’ FDA Win Reinforces BofA’s Bullish Thesis

The U.S. Food and Drug Administration approval of GW Pharmaceuticals PLC (NASDAQ: GWPH)’s epidiolex therapy for the treatment of seizures was expected — and reinforces the bullish case for owning the stock, according to Bank of America Merrill Lynch. Continue reading “GW Pharmaceuticals’ FDA Win Reinforces BofA’s Bullish Thesis”

GW Pharma Responds: ‘Not Creating a Monopoly’

British drug manufacturer GW Pharma and its American subsidiary, Greenwich BioSciences, have responded to Leafly’s report last week about the company’s attempts to move proprietary cannabidiol (CBD) bills through at least two state legislatures.

GW/Greenwich says it is not opposing medical marijuana or CBD access. Continue reading “GW Pharma Responds: ‘Not Creating a Monopoly’”

GW Pharma Takes A Step Toward Diversifying

Being a one-trick pony can always prove risky. This rationale seems to have dawned on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), a biopharmaceutical company specializing in prescription cannabinoid medicine. Continue reading “GW Pharma Takes A Step Toward Diversifying”